 | | Vol. 14.08 – 3 March, 2023 |
| |
|
|
| Scientists profiled the N-linked glycans in tumor tissue derived from 131 prostate cancer patients to identify glycosylation changes associated with loss of tumor cell differentiation, therapy resistance, and disease recurrence, as well as neuroendocrine differentiation which is a major mechanism for therapy failure.
[Npj Precision Oncology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers observed that NRP1 was highly expressed in prostate cancer and associated with poor prognosis in prostate cancer patients.
[Cell Death & Disease] |
|
|
|
| Scientists investigated the role of tropomyosins 2 (TPM2), PDLIM7, and YAP1 in prostate progression and castration resistance.
[Cell And Bioscience] |
|
|
|
| Investigators demonstrated that prostate-specific membrane antigen (PSMA) expression was heterogeneous across different metastatic sites and molecular subtypes of metastatic castration-resistant prostate cancer.
[JCI Insight] |
|
|
|
| Researchers found that Trigred motif 36 was lowly expressed in neuroendocrine prostate cancer, and its overexpression suppressed the neuroendocrine differentiation of prostate cancer.
[Cancer Science] |
|
|
|
| Scientists investigated the specific mechanism through which dibutyl phthalate promoted prostate cancer cell proliferation. They found protective measures – Natura-α which could be helpful to mitigate this effect.
[Toxicology] |
|
|
|
| Investigators demonstrated that cannabidiol was a viable therapy to treat prostate cancer cells, in combination with the silencing of retinoblastoma binding protein 6 (RBBP6). This suggested that cannabidiol rather Cannabis sativa extract may play an important role in reducing cancer progression.
[Molecular Biology Reports] |
|
|
|
| Researchers studied the role of euchromatic histone lysine methyltransferase 2 (EHMT2) and endoplasmic reticulum protein 29 (ERP29) in the progression of radioresistance in prostate cancer.
[Kaohsiung Journal Of Medical Sciences] |
|
|
|
| Scientists used docetaxel-resistant cell lines DU145/DTX50 and PC-3/DTX30 to measure the responses to cabazitaxel.
[Archives Of Biochemistry And Biophysics] |
|
|
|
|
| The authors introduce a large number of predictive molecules related to prostate cancer metastasis. These molecules involve the mutation and regulation of tumor cell genes, changes in the tumor microenvironment, and the liquid biopsy.
[Expert Review Of Molecular Diagnostics] |
|
|
|
| Investigators focus on protein kinase D (PrKD) signaling in prostate cancer and the potential role of PrKD inhibitors therein and explore the possible clinical outcomes based on known function and expression of PrKD isoforms at different stages of prostate cancer.
[Journal Of Molecular Medicine] |
|
|
|
|
| The European Commission granted marketing authorization in the European Union for darolutamide, an oral androgen receptor inhibitor, plus androgen deprivation therapy in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer.
[Orion, Corp.] |
|
|
|
|
| March 19 – 21, 2023
Sitges, Spain |
|
|
|
|
|
| | University of Miami – Miami, Florida, United States |
|
|
|
| | University of Tasmania – Tasmania, Australia |
|
|
|
| | The Henry Ford Health System – Detroit, Michigan, United States |
|
|
|
| | Vancouver Prostate Centre – Vancouver, British Columbia, Canada |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
